Sep 30 |
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
|
Sep 3 |
Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
Aug 13 |
Galectin Therapeutics GAAP EPS of -$0.20
|
Aug 13 |
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
|
Aug 1 |
Galectin Therapeutics appoints Khurram Jamil as chief medical officer
|
Aug 1 |
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
|
Jul 30 |
Galectin Therapeutics Inc.'s (NASDAQ:GALT) largest shareholders are retail investors with 57% ownership, insiders own 20%
|
Jul 24 |
Galectin Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying
|
Jun 7 |
Galectin Therapeutics: Neutral On Belapectin For NASH Cirrhosis Amid Financial Challenges
|
Jun 4 |
Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress
|